Proactive investors

International Stem Cell Corporation ist ein Biotechnik-Unternehmen. Es konzentriert sich auf die biomedizinische Recherche.

• 12/10/2011 International Stem Cell meldet positive erste Ergebnisse in Versuchen mit neuronalen Stammzellen
• 05/10/2011 International Stem Cells Lifeline Geschäftsbereich startet neue Marketing-Initiative
• 17/06/2011 International Stem Cell ernennt Marketing Manager für Lifeline Produkte
• 20/05/2011 International Stem Cell registriert ersten US Spender für Stammzellenbank
• 09/05/2011 International Stem Cell Corp hat erhebliche Fortschritte gemacht

• 17/11/2011 International Stem Cell meldet Umsatzanstieg im dritten Quartal
• 11/11/2011 International Stem Cells zeichnet Vertriebsabkommen für Lifeline Produkte
• 07/10/2011 International Stem Cell ernennt Kurt May als Chief Operating Officer
• 29/09/2011 International Stem Cell ernennt Linh Nguyen als Finanzvorstand
• 21/07/2011 International Stem Cell startet vorklinische Versuche mit neuronalen Stammzellen

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, Parthenogenesis, results in creation of pluripotent human stem cells ("hpSCs") from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos and can be a source of therapeutic cells that minimize or eliminate immune rejection after transplantation into the patient.

Kenneth C. Aldrich, Chairman and Co-Founder . Mr. Aldrich has been active in venture capital investing and private equity since 1975. He is Co-founder and Chairman of International Stem Cell Corporation (ISCO), a Managing Director of Convergent Ventures, an early-stage life sciences investment company, and an active member of Tech Coast Angels. Through those entities and predecessor companies, he has provided early-stage funding and management for a variety of biomedical and technology start-ups, including WaveTec Vision Systems, an ophthalmic device company (as a Director and co-founder), Neurion Pharmaceuticals, Inc., a drug discovery and evaluation company (as a Director and co-founder), and Orfid Corporation, a developer of organic transistors (as a founder and financial advisor). He is also a director of Green Dot Corporation, the world’s largest issuer of prepaid debit cards. Mr. Aldrich holds degrees, with honors, from both Harvard University and Harvard Law School.

Andrey Semechkin, Professor, Ph. D., Director and CEO . Dr. Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis since 2004. Professor Semechkin was awarded the Russian Government Award in Science and Technology in 2006 and has written several scientific books. He has over 20 years experience creating and managing businesses across different industries and scientific sectors. He was CEO of X-Master Inc., a private U.S. company with real estate and other investments.

Jeffrey Janus, Director , Sr. Vice President Operations and President and CEO of Lifeline Cell Technology. Mr. Janus has a proven track record extending over eighteen years of creating profitable commercial cell based businesses and building corporate value as a result. Jeffrey was a founder of Lifeline Cell Technology, the keystone company to ISCO’s portfolio of cellular companies. He led in the development and commercialization of Clonetics Corporation and the Clonetics brand of human cell products for both research and clinical use. Clonetics is the leading brand of human-cell based products, well known for quality and innovation. That company was successfully sold in 1995 after ten consecutive years of profitable growth exceeding 20%. Mr. Janus foresaw the need for human cells in therapy and created businesses in the contract manufacturing of human cells and culture media and human cells for clinical use. He has organized businesses providing unique research products using living cells to conduct drug screening in the pharmaceutical industry, product testing in the consumer products industry and basic research at Universities and Government laboratories. Critical staff from Clonetics Corporation agreed to join Lifeline largely based on the success of working Mr. Janus in the past. Mr. Janus has a MBA and a Bachelor's degree in Biochemistry.

Paul Maier, Director . Mr. Maier has over 20 years of experience as a senior executive in biotechnology and pharmaceutical companies. Mr. Maier is currently an independent financial consultant.

Previously, Mr. Maier was Senior Vice President and Chief Financial officer of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From 1990 to 1992, Mr. Maier served as Vice President, Finance of DFS West, a division of DFS Group, LP a private multinational retailer. From 1984 to 1990, Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier has served on the boards of public and private companies. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Donald Wright, Director . Mr. Wright brings to International Stem Cell Corporation over 30 years of experience in starting and nurturing emerging growth companies, both public and private. He is President and Founder of Everett, Washington-based Confluence Capital Group Inc., (www.confluencecap.com), which provides consulting services to institutional investors, debt holders and public and private companies.

Prior to Confluence Capital, Mr. Wright was President and CEO of Pacific Aerospace & Electronics, Inc., a company he founded in 1990, took public and ran until 2006. Under his leadership, Pacific Aerospace grew from annual sales of approximately $3 million in 1994 to over $112 million in 2000. Earlier, Mr. Wright was President and CEO of Washington-based Component Concepts, Inc., a company he founded in 1976. He is the recipient of numerous business and community awards, and was named one of the 50 fastest growing companies in Washington State for 1998, 1999 and 2000 by Deloitte & Touche. Additionally he was recognized by Deloitte & Touche as one of the 500 fastest growing companies in the United States for 1998, 1999 and 2000.

Mr. Wright served as an advisory board member for Central Washington University’s School of Business for six years and completed the UCLA Director Training and Certification Program.

Charles J. Casamento, Director, is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr. Casamento also serves on the Boards of Directors of CORTEX Pharmaceuticals, SuperGen, Inc. and VIVUS, Inc. He holds a bachelor's degree in Pharmacy from Fordham University and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey.

Ruslan Semechkin, PhD, Director, Vice President and President and CEO of Lifeline Skin Care. Dr. Semechkin is a specialist in analysis of biological processes and mathematical modeling in biology. He is an honors graduate from the Moscow State University and a member of the American Mathematical Society. Dr. Semechkin brings to ISCO both scientific expertise and international relationships.

No info available.

• Medical Australia Limited (ASX: MLA)